Point mutation in mitochondrial tRNA gene is associated with polycystic ovary syndrome and insulin resistance

YU DING¹, GUANGCHAO ZHUO¹ CAIJUAN ZHANG¹,² and JIANHANG LENG¹

¹Central Laboratory and ²Department of Obstetrics and Gynecology, Hangzhou First People’s Hospital Affiliated to Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China

Received March 25, 2015; Accepted January 20, 2016

DOI: 10.3892/mmr.2016.4916

Abstract. Polycystic ovarian syndrome (PCOS) is characterized by chronic anovulation, hyperandrogenism and polycystic ovaries. To date, the molecular mechanisms underlying PCOS have remained to be fully elucidated. As recent studies have revealed a positive association between mitochondrial dysfunction and PCOS, current investigations focus on mutations in the mitochondrial genome of patients with POCS. The present study reported a Chinese patient with PCOS. Sequence analysis of the mitochondrial genome showed the presence of homoplasmic ND5 T12338C and tRNA^{Ser(UCN)} C7492T mutations as well as a set of polymorphisms belonging to the human mitochondrial haplogroup F2. The T12338C mutation is known to decrease the ND5 mRNA levels and to inhibit the processing of RNA precursors. The C7492T mutation, which occurred at the highly conserved nucleotide in the anticodon stem of the tRNA^{Ser(UCN)} gene, is important for the tRNA steady-state level as well as the aminoacylation ability. Therefore, the combination of the ND5 T12338C and tRNA^{Ser(UCN)} C7492T mutations may lead to mitochondrial dysfunction, and is likely to be involved in the pathogenesis of PCOS. The present study provided novel insight into the molecular mechanisms of PCOS.

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-age women, affecting 8-18% (1). Insulin resistance (IR) is considered to be the main pathological factor responsible for the hormonal disturbances associated with the syndrome (2), and IR in PCOS patients confers a substantial risk for developing type 2 diabetes and cardiovascular diseases (3,4). Furthermore, IR has been reported to be linked with reduced mitochondrial respiration (5). Reduced expression of nuclear-encoded genes involved in oxidative phosphorylation (OXPHOS) has been reported in skeletal muscle of patients with PCOS (6). In addition, analysis of oxygen consumption in blood mononuclear cells (leukocytes) indicated that in women with PCOS, mitochondrial complex I respiration is reduced compared with that in age- and body mass index-matched control subjects (7). Due to this central role of mitochondrial impairment in PCOS, current studies focus on mutations in the mitochondrial genome of patients with POCS.

With the purpose of elucidating the molecular basis of PCOS, the present study performed a systematic and extensive mutational screening for pathogenic mutations in the mitochondrial genome of a patient with PCOS. Previous studies by our group showed that mitochondrial OXPHOS complexes are hot spots for mutations associated with PCOS, as well as several mitochondrial transfer (mt-t)RNA mutations (8,9). These tRNA mutations included tRNA^{Glu} T4395C, tRNA^{Gly} G5821A, tRNA^{A^1} A7543G, tRNA^{A^2} A8343G, tRNA^{A^3} T10454C and tRNA^{Glu} A14693G. These mt-tRNA mutations were localized at highly conserved nucleotides, which caused structural and functional alternations, and consequently resulted a failure of mt-tRNA metabolism. The present study reported on the clinical and molecular characterization of a Han Chinese patient with PCOS-IR. A sequence analysis of the mitochondrial genome showed the presence of ND5 T12338C and tRNA^{Ser(UCN)} C7492T mutations.

Subject and methods

Case subject. A female patient (age, 31 years) from the Hangzhou area of Zhejiang Province (China) was referred to the Department of Obstetrics and Gynecology (Hangzhou First People’s Hospital, Hangzhou, China) due to an irregular menstrual cycle and suspicion of PCOS. Following obtention of written informed consent from the patient, blood samples were obtained and a clinical evaluation was performed following protocols approved by the Ethics Committee of Hangzhou First People’s Hospital (Hangzhou, China). The patient underwent a thorough physical examination,
laboratory assessment of metabolic syndrome and routine electrocardiography. In addition, 200 age-matched control subjects (average age, 30 years) were selected from a panel of unaffected women of Han Chinese ancestry from the same region. A thorough analysis of the patient’s personal and the patient’s family’s medical history was performed, the patient’s symptoms were assessed and PCOS was diagnosed according to the Rotterdam criteria (10): i) Clinical signs of hyperandrogenism; ii) polycystic ovaries symptom; iii) A ratio of luteinizing hormone (LH) levels vs. follicle stimulating hormone (FSH) of >2.0, or total testosterone levels of >2.64 nmol/l. In addition, a comprehensive physical examination of the patient was performed to confirm the absence of any other syndrome, including hyperprolactinemia, thyroid and adrenal diseases, 21-hydroxylase deficiency and androgen-secreting tumors. The patient had no family history of PCOS.

**Laboratory assessment.** Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, progesterone, total testosterone (TT) and fasting insulin levels were measured by electrochemiluminescence immunoassays (Roche Diagnostics, Basel, Switzerland). The plasma glucose levels were measured using a Beckman glucose analyzer (Ramcon, Fullerton, CA, USA). Furthermore, an oral glucose tolerance test was performed. In brief, a blood sample was obtained from the antecubital vein at 0 and 120 min for measurement of plasma glucose concentrations, with 0 min denoting the level of fasting plasma glucose. Patients with a plasma glucose concentration of <7.8 mmol/l at the 120-min time point were categorized as having normal glucose tolerance, while those with plasma glucose levels of 7.8-11.1 mmol/l were classified as having impaired glucose tolerance, and those with glucose levels of >11.1 mmol/l were indicated to have diabetes mellitus. The main outcome measure of IR was calculated using the homeostatic model assessment of IR (HOMA-IR), where a value of >3.16 denotes IR according to the following formula:

\[
\text{HOMA-IR} = \frac{\text{fasting glucose} \times \text{insulin}}{22.5}
\]

**Molecular and genetic analysis.** Total DNA was isolated from peripheral blood leukocytes of the patient using an Universal Genomic DNA Extraction kit version 3.0 (Takara Bio Inc., Otsu, Japan). The entire mtDNA was amplified in 24 overlapping primers as previously described (11), using 24 overlapping primers provided by the BGI (Shenzhen, China). The PCR mixture included 200 µM dNTPs, 2 µl buffer (10X), 0.2 µl Taq DNA polymerase and 15 mmol/l Mg2+ (Takara Bio Inc., Otsu, Japan). After polymerase chain reaction amplification, the fragments were purified and subsequently analyzed by direct sequencing in an ABI 3730 automatic DNA sequencer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) using the BigDye Terminator Cycle Sequencing kit (Sigma-Aldrich, St. Louis, MO, USA). Sample sequences were compared with the revised Cambridge Reference Sequence (GenBank accession no. NC_012920) from MITOMAP, a human mitochondrial genome database (http://www.mitomap.org/MITOMAP) (12).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH (IU/l)</td>
<td>14.54</td>
<td>1.50-9.30</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td>5.17</td>
<td>1.40-18.00</td>
</tr>
<tr>
<td>Estradiol (pmol/l)</td>
<td>205.60</td>
<td>0.00-198.20</td>
</tr>
<tr>
<td>Progesterone (nmol/l)</td>
<td>3.12</td>
<td>0.89-3.88</td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>2.89</td>
<td>8.36-28.70</td>
</tr>
<tr>
<td>Prolactin (µg/l)</td>
<td>5.22</td>
<td>2.00-17.00</td>
</tr>
<tr>
<td>OGTT (0 h) (mmol/l)</td>
<td>5.11</td>
<td>3.90-6.10</td>
</tr>
<tr>
<td>OGTT (2 h) (mmol/l)</td>
<td>8.55</td>
<td>-</td>
</tr>
<tr>
<td>Insulin (0 h) (µU/ml)</td>
<td>9.80</td>
<td>2.60-12.00</td>
</tr>
<tr>
<td>HOMA-IR (x)</td>
<td>3.72</td>
<td>-</td>
</tr>
</tbody>
</table>

LH, luteinizing hormone; FSH, follicle-stimulating hormone; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment of insulin resistance.

**Results and Discussion.**

Laboratory examination of the patient showed that the levels of TT were 2.89 nmol/l, and the LH/FSH ratio was 2.81. In addition, the patient was insulin resistant. The clinical laboratory parameters of the PCOS patient are listed in Table I.  

**Table I. Clinical and biochemical parameters of the patient with polycystic ovary syndrome.**

Mutational screening of the mitochondrial genome showed the presence of the homoplasmic ND5 T12338C and tRNA<sup>Ser</sup>(UCN) C7492T mutations (Fig. 1), belonging to the human mitochondrial haplogroup F2 (13). Notably, the homoplasmic ND5 T12338C mutation was only detected in the patient with PCOS but not in the healthy controls. This mutation is a result of a replacement of the first amino acid, a translation-initiating methionine, with a threonine in the ND5 polypeptide (Fig. 2). The encoding sequence of the first methionine in the ND5 gene is extraordinarily conserved among species and organ-elles ranging from bacteria to human mitochondria (14). As a result, the truncated ND5 protein was expected to be shortened by two amino acids, since the ND5 T12338C mutation replaced the first amino acid from methionine to threonine and, as methionine is the translational initiation code, the mutant ND5 translates from the third methionine. As reported by a previous study, the ND5 T12338C mutation was also located in two nucleotides adjacent to the 3′ end of the tRNA<sup>Leu</sup> (CUN) gene (15). Consequently, this mutation altered respiratory function, as well as the processing of RNA precursors, thereby leading to a reduction in tRNA<sup>Leu</sup> (CUN) levels. The functional significance of the ND5 T12338C mutation in terms of mitochondrial physiology was further supported by studies reporting that the T12338C mutation may modulate the phenotypic expression of the deafness-associated 12S rRNA A1555G mutation, and that it was associated with essential hypertension and Leber’s hereditary optic neuropathy (16,17). The homoplasmicNDI T3308C mutation has been suggested to contribute to the higher penetrance of hearing loss in a large African pedigree compared with that in Japanese and French pedigrees carrying the tRNA<sup>Ser</sup> (UCN) T751C mutation (18,19). A significant reduction in steady-state levels of ND1 mRNA
Figure 1. Identification of the T12338C and C7492T mutations in the mitochondrial genome. Partial sequence of the ND5 and tRNA\textsubscript{Ser (UCN)} genes from the patient and controls. Arrows indicate the positions of 12,338 and 7,492 bp.

Figure 2. Scheme of the mitochondrial DNA sequence at 12,338 bp and the adjacent sequence of ND5 and tRNA\textsubscript{Leu (CUN)} in the wild and mutant types. Arrows indicate the position of the T12338C mutation. WT, wild-type; MT, mutant type.

Figure 3. Secondary structure of the gene encoding mitochondrial tRNA\textsubscript{Ser (UCN)}. The arrow indicates the C7492T mutation.

Figure 4. Alignment of tRNA\textsubscript{Ser (UCN)} gene in various species. The arrow indicates position 26, corresponding to the C7492T mutation.
and the adjacent tRNA^{Leu}(UUR) observed in cybrids carrying the T3308C mutation was likely due to an alteration in the processing of the H-strand polycistronic RNA precursors or the destabilization of ND1 mRNA (20). Thus, the ND5 T12338C mutation, which is similar to the ND1 T3308C mutation (14,19), may induce a reduction in ND5 mRNA expression levels, as well as the steady state level of tRNA^{Ser}(UCN); therefore, this mutation may cause mitochondrial dysfunction and, since mitochondrial dysfunction is associated with the pathogenesis of PCOS-IR (6,7), we propose the ND5 T12338C mutation is associated with PCOS-IR.

The homoplasmic C7492T mutation occurred at position 26 in the anticodon stem of the tRNA^{Ser}(UCN)-encoding gene (Fig. 3). Mutation at this position is highly conserved among various species, which suggests that it may be associated with the pathogenesis of PCOS-IR (Fig. 4). In addition, the C7492T mutation led to an alteration of base pairing (A26-U44), and identical base pairing at the same position in tRNA^{Ser} generated by the heteroplasmic T4295C mutation has been associated with altered tRNA metabolism in chronic progressive external ophthalmoplegia (21). Therefore, it can be anticipated that the C7492T mutation may alter the tertiary structure of tRNA^{Ser}(UCN) and, since the anticodon stem is critical for codon and anticodon interaction, this mutation may reduce the steady state level of tRNA^{Ser}(UCN) as well as the aminocacylation ability. The resultant shortage of tRNA^{Ser}(UCN) may be responsible for defects in mitochondrial protein synthesis. Consequently, the deficiency in respiratory chain function will cause a reduction in ATP synthesis and increase the generation of reactive oxygen species. Therefore, this mutation may have an active role in the pathogenesis of PCOS-IR. However, due to the complex molecular mechanisms of PCOS, it is likely that the C7492T and T12338C mutations alone are insufficient to produce the clinical phenotype; other factors, including nuclear genes, epigenetic modifications and environmental factors may contribute to the pathogenesis of PCOS.

Acknowledgements

The authors would like to thank the patient for participating this study. This work was supported by grants from the Ministry of Public Health of Zhejiang Province (grant no. 2013KYA158) and the Hangzhou Bureau of Science and Technology (grant no. 20150633B16).

References